While the methodology and approach is sound the study protocol does not address fully how it will turn up anything new that has not already been discussed in the previous couple of years. The knowledge gaps on safety and primaquine are fairly well known, and the studies required to address these are only recently been initiated. The value of this review will depend on the timing. If done immediately it is not clear what new perspectives it will raise, beyond re-enforcing the knowledge gaps and need for more evidence.
GENERAL COMMENTS
The protocol for this review is well written. I suggest that there should be stratification of malaria transmission as one of the parameters to be examined -The reviewer also provided a marked copy with comments. Please contact the publisher for full information.
REVIEWER
Toby Leslie LSHTM, UK REVIEW RETURNED 13-Mar-2014
GENERAL COMMENTS
A good protocol for a systematic review of literature on single dose primaquine and its safety. This is of high importance at the moment and is likely to be of interest to a specialist audience as it is being considered for use in malaria control in certain settings in Africa and Asia.
A few comments that the authors might find useful:
1) A limitation of any study on G6PD and PQ risks is that most reports of safety concerns in primaquine administration are published as case reports, which have no denominator, and make risk assessment more subjective.
2) Reduction in gametocytes does not necessarily result in reduced transmissionwhich depends on parasite density, stage of the gametocyte, host immunology and vector competence (as well as other factors known and unknown).
3) The objective of the systematic review is to: "estimate the risk of adverse events". The estimation of risk implies a meta-analysis since it is a statistical process, but I am not sure if that is what is intended here. I suggest rephrasing that to "review the evidence on risk of adverse events". As the authors mention later in the protocol, they may do a meta-analysis if the data will stand up to it. But this may not happen, and that could effect the primary objective. 4) The authors will include G6PD deficiency only if measured using quantitative means (% enzyme activity) or using genotype. I feel this may be unduly restrictive since the most common test is probably the qualitative test (FST). I would suggest also including these, even though it does not provide a quantitative test, it does identify people with approx <30% activity. 5) It would also be worth considering a stratified analysis in males and females because the risks of functional deficiency are different (as you point out in the introduction).
Lastly, the major problem with this risk assessment is not the numerator, but the denominator. This will require careful assessment and evaluation as it could significantly alter the outcome and therefore the decision to use PQ more widely or not.
VERSION 1 -AUTHOR RESPONSE
Reviewer Name Gonzalo Domingo While the methodology and approach is sound the study protocol does not address fully how it will turn up anything new that has not already been discussed in the previous couple of years. The knowledge gaps on safety and primaquine are fairly well known, and the studies required to address these are only recently been initiated. The value of this review will depend on the timing. If done immediately it is not clear what new perspectives it will raise, beyond re-enforcing the knowledge gaps and need for more evidence.
Authors' reply: To the best of knowledge, to date, there is no systematic review specifically designed to assess the risk of haemolysis in people with G6PD deficiency given primaquine or other 8aminoquinoline (8AQ) as a single dose or short course (less than seven days). Though there is one unpublished review, it did not attempt to examine the accuracy or quality of the primary studies measuring risk. We will update the systematic review and meta-analysis as more pivotal studies are published.
Reviewer Name Olugbenga Mokuolu
The protocol for this review is well written. I suggest that there should be stratification of malaria transmission as one of the parameters to be examined Authors' reply: Thanks, we have now included malaria transmission stratification where data allow.
Reviewer Name Toby Leslie A good protocol for a systematic review of literature on single dose primaquine and its safety. This is of high importance at the moment and is likely to be of interest to a specialist audience as it is being considered for use in malaria control in certain settings in Africa and Asia. Authors' reply: Thanks for your comments.
1) A limitation of any study on G6PD and PQ risks is that most reports of safety concerns in primaquine administration are published as case reports, which have no denominator, and make risk assessment more subjective. Authors' reply: Thanks for pointing that out, we assess risk of bias that could be introduced due to poor or improper reporting of the adverse events.
2) Reduction in gametocytes does not necessarily result in reduced transmissionwhich depends on parasite density, stage of the gametocyte, host immunology and vector competence (as well as other factors known and unknown). Authors' reply: This is clarified in the background section that "There remains a debate about whether this will result in meaningful reduction in transmission on a population basis"
3) The objective of the systematic review is to: "estimate the risk of adverse events". The estimation of risk implies a meta-analysis since it is a statistical process, but I am not sure if that is what is intended here. I suggest rephrasing that to "review the evidence on risk of adverse events". As the authors mention later in the protocol, they may do a meta-analysis if the data will stand up to it. But this may not happen, and that could effect the primary objective. Authors' reply: The objective has now been rephrased "To assess the risk of haemolysis in people with G6PD deficiency given primaquine or other 8-aminoquinoline (8AQ) as a single dose or short course (less than seven days)."
4) The authors will include G6PD deficiency only if measured using quantitative means (% enzyme activity) or using genotype. I feel this may be unduly restrictive since the most common test is probably the qualitative test (FST). I would suggest also including these, even though it does not provide a quantitative test, it does identify people with approx <30% activity. Authors' reply: This has been clarified "Adults or children who have been tested for G6PD deficiency, using percentage enzyme activity, genotype, rapid fluorescent spot test or any other method as reported by the authors of the primary study."
5) It would also be worth considering a stratified analysis in males and females because the risks of functional deficiency are different (as you point out in the introduction). Authors' reply: This has been included under subgroup analysis Lastly, the major problem with this risk assessment is not the numerator, but the denominator. This will require careful assessment and evaluation as it could significantly alter the outcome and therefore the decision to use PQ more widely or not. Authors' reply: Thanks, this issue is noted and will be assessed appropriately.
